Correction: Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunich^LMU Molecular Tumor Board.

IF 4 3区医学 Q2 ONCOLOGY

Targeted Oncology Pub Date : 2025-09-01 DOI:10.1007/s11523-025-01171-3

Klara Dorman, Christoph J Auernhammer, Christine Spitzweg, Ralf Schmidmaier, Svenja Nölting, Matthias Kroiss, Martin Reincke, Christian Schulz, Martin Angele, Jens Werner, Christine Schmid-Tannwald, Josefine Rauch, Mathias Zacherl, Thomas Knösel, Jörg Kumbrink, Andreas Jung, Frederick Klauschen, Amanda Tufman, Danmei Zhang, Lena Weiss, Stefan Boeck, Michael von Bergwelt-Baildon, Volker Heinemann, C Benedikt Westphalen, Kathrin Heinrich

引用次数: 0

查看原文本刊更多论文

修正：罕见内分泌和神经内分泌肿瘤的精确肿瘤学：CCCMunichLMU分子肿瘤委员会的经验和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Targeted Oncology 医学-肿瘤学

CiteScore

8.40

自引率

3.70%

发文量

审稿时长

>12 weeks

期刊介绍： Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes: Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches. Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways. Current Opinion articles that place interesting areas in perspective. Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations. Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement. Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

Correction: Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.

Correction: Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunich^LMU Molecular Tumor Board.